Request Trial
18 July 2025VideosAmericasJohn Rearick, Dechert | Michael Penn, BlueRock Therapeutics | Mark Stewart, Merck | Paul Fleming, Seaport Therapeutics | Robin Weatherhead, Ventus Therapeutics

WATCH: Enabling success—mastering s112 in the new era of life sciences patents

Experts from Dechert, BlueRock Therapeutics, Merck, Seaport Therapeutics, and Ventus Therapeutics examine the impact of recent court rulings following Amgen v. Sanofi on broad genus claims within life sciences patents, as discussed at LSPN.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Mylan withdraws defence claims against Novo in Wegovy dispute
13 March 2026   A proposed judgment by the rivals would extend the period in which Mylan is barred from obtaining regulatory approval for its generic of the weight-loss injectable.
Americas
Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks
12 March 2026   The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.
Americas
Astellas blocks generic version of key urology drug until 2030
12 March 2026   The pharma company has successfully enforced its patents against Ascent’s proposed mirabegron copy, shortly after inking licensing deals elsewhere over the medication.


Editor's picks

Abbott IP chief: ‘Firms without AI policies scare me’
Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026

Editor's picks

Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026
Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026

More features

Mylan withdraws defence claims against Novo in Wegovy dispute
Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks
Astellas blocks generic version of key urology drug until 2030
GSK inks licensing deal for liver disease drug
Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs
Medtech Magnolia fails to revive $2.1m verdict at Fed Circ
Nomination call: Influential Women in IP list closes ahead of International Women’s Day
Abbott IP chief: ‘Firms without AI policies scare me’